Skip to main content
    4

    4D Molecular Therapeutics Inc (FDMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.87
    +0.67 (+5.49%)

    Market Cap: $673.98M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(12/24)
    Avg Surprise
    -26.05%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.05
    Range$-1.10 - $-0.99
    11 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.01-3.6%
    60d ago$-1.02-3.0%
    30d ago$-1.04-0.7%
    7d ago$-1.04-0.9%
    Current$-1.05
    Revenue Consensus
    $3M
    Range$0 - $6M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.09
    Range$-1.24 - $-0.94
    11 analysts
    Revenue Consensus
    $5M
    Range$-1600120 - $14M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.09---
    Sep 26EST
    		-$-1.05---
    Jun 26
    Reported Aug 13
    		$-1.04$-1.04+0.00%Beat-6.1%
    Mar 26
    Reported May 7
    		$-1.01$-1.00-1.00%Miss-17.4%
    Dec 25
    Reported Mar 18
    		$0.43$-0.53+180.83%Beat+147.8%
    Sep 25
    Reported Nov 10
    		$-1.01$-0.98-3.06%Miss-27.8%
    Jun 25
    Reported Aug 11
    		$-0.98$-0.69-42.03%Miss-55.6%
    Mar 25
    Reported May 8
    		$-0.86$-0.86+0.00%Beat-30.3%
    Dec 24
    Reported Feb 28
    		$-0.90$-0.84-7.41%Miss-20.0%
    Sep 24
    Reported Nov 13
    		$-0.79$-0.70-12.86%Miss-229.2%
    Jun 24
    Reported Aug 8
    		$-0.63$-0.71+11.27%Beat+18.2%
    Mar 24
    Reported May 9
    		$-0.66$-0.76+13.16%Beat+25.0%
    Dec 23
    Reported Feb 29
    		$-0.75$-0.74-1.35%Miss+10.7%
    Sep 23
    Reported Nov 9
    		$-0.24N/A+60.00%Beat+69.6%
    Jun 23
    Reported Aug 9
    		$-0.77$-0.77+0.00%Beat+11.5%
    Mar 23
    Reported May 10
    		$-0.88$-0.90+2.22%Beat-7.3%
    Dec 22
    Reported Mar 15
    		$-0.84$-0.79-6.33%Miss+1.2%
    Sep 22
    Reported Nov 8
    		$-0.79$-0.91+13.19%Beat+3.7%
    Jun 22
    Reported Aug 11
    		$-0.87$-0.85-2.35%Miss-210.7%
    Mar 22
    Reported May 12
    		$-0.82$-0.77-6.49%Miss-34.4%
    Dec 21
    Reported Mar 28
    		$-0.85$-0.86+1.16%Beat+64.0%
    Sep 21
    Reported Nov 10
    		$-0.82$-0.80-2.50%Miss+73.3%
    Jun 21
    Reported Aug 12
    		$-0.28N/A+58.82%Beat+91.0%
    Mar 21
    Reported May 13
    		$-0.61$-1.10+44.55%Beat+66.5%
    Dec 20
    Reported Mar 25
    		$-2.36$-0.66-257.58%Miss-46.7%
    Sep 20
    Reported Dec 16
    		$-3.07$-0.40-667.50%Miss-90.8%
    Sep 19
    Reported Dec 31
    		$-3.12$0.00N/AMiss-626.2%
    Jun 19
    Reported Sep 30
    		$-1.82$0.00N/AMiss-323.5%
    Mar 19
    Reported Jun 29
    		$-1.61$0.00N/AMiss-211.6%
    Dec 18
    Reported Mar 30
    		$-1.61$0.00N/AMiss-211.6%
    Sep 18
    Reported Dec 31
    		$-0.43$0.00N/AMiss-
    Jun 18
    Reported Sep 30
    		$-0.43$0.00N/AMiss-
    Mar 18
    Reported Jun 29
    		$-0.52$0.00N/AMiss-
    Dec 17
    Reported Mar 30
    		$-0.52$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.89EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-194.70%Operating Margin-2037.00%
    ROE-43.20%ROIC-36.49%
    Financial Health
    Debt/Equity0.05xInterest CoverageN/A
    Current Ratio8.03xQuick Ratio8.03x
    Trading Statistics
    Beta2.74Avg Volume1.09M
    52-Week High$16.9352-Week Low$6.96

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.82
    SMA 20$13.80
    SMA 50$13.88
    SMA 200$10.62
    EMA 10$12.96
    EMA 20$13.37
    EMA 50$13.33
    EMA 200$11.10

    MACD

    Line: -0.41Signal: -0.25Hist: -0.16

    ADX

    ADX: 16.2+DI: 19.3-DI: 24.0

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down96.0
    PSAR$13.92

    Bollinger Bands

    Upper Band$16.03
    Lower Band$11.56
    %B Position3246%(Upper)
    Band Width0.29

    RSI (14-Day)

    Neutral
    44.0

    Momentum Oscillators

    Stoch %K15.0
    Stoch %D16.0
    Williams %R-70.5
    ROC (10d)-7.0%
    Momentum-0.97
    CCI (20d)-80.5
    MFI (14d)21.1

    Volatility Measures

    ATR (14d)$0.88(6.8%)
    StdDev (20d)1.12
    Hist Vol51.6%(High)

    Volume Flow

    VWAP$12.64
    OBV46.1M
    AD Line19.8M
    CMF (20d)-0.053

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.7x
    VWMA (20d)$13.92

    Pivot Points

    R3$13.11
    R2$12.85
    R1$12.52
    Pivot Point$12.26
    S1$11.93
    S2$11.67
    S3$11.34

    Advanced Oscillators

    TSI-15.19
    Ultimate Osc50.9
    KST-97.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.78M$3.05M$85.21M$0$15,000$0$1,000$0$0$0$519,000$20.20M
    Cost of Revenue$0$0$1.98M$0$0$0$1.78M$0$0$0$26.03M$0
    Gross Profit$3.78M$3.05M$85.21M$0$15,000$0$-1,783,000$0$0$0$519,000$20.20M
    Operating Expenses$80.81M$76.67M$70.38M$61.27M$59.47M$53.63M$56.12M$51.13M$42.46M$38.16M$36.63M$34.18M
    R&D$68.28M$64.98M$57.61M$49.44M$47.95M$40.70M$43.09M$38.48M$31.86M$27.87M$26.03M$25.07M
    SG&A$12.52M$11.69M$12.77M$11.84M$11.52M$12.94M$13.03M$12.65M$10.60M$10.29M$10.60M$9.11M
    Operating Income$-77,025,000$-73,620,000$14.71M$-61,185,000$-59,456,000$-53,621,000$-56,117,000$-51,132,000$-42,456,000$-38,136,000$-36,651,000$-13,974,000
    Interest Income$4.25M$4.86M$4.70M$4.33M$4.86M$5.58M$6.47M$7.29M$7.55M$5.75M$4.38M$3.88M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-72,936,000$-68,760,000$19.40M$-56,876,000$-54,658,000$-47,972,000$-49,671,000$-43,843,000$-34,953,000$-32,401,000$-32,283,000$-10,256,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-72,936,000$-68,760,000$19.40M$-56,876,000$-54,658,000$-47,972,000$-49,671,000$-43,843,000$-34,953,000$-32,401,000$-32,283,000$-10,256,000
    EBITDA$-76,092,000$-72,703,000$15.53M$-60,357,000$-58,795,000$-53,067,000$-56,204,000$-51,670,000$-43,212,000$-37,309,000$-35,629,000$-12,886,000
    EBIT$-77,191,000$-73,624,000$14.69M$-61,206,000$-59,517,000$-53,554,000$-56,138,000$-51,133,000$-42,501,000$-38,146,000$-36,663,000$-14,132,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FDMT

    News

    Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Viking Therapeutics (VKTX)

    Chardan Capital and Morgan Stanley analysts have issued bullish ratings for 4D Molecular Therapeutics (FDMT) and Viking Therapeutics (VKTX)...

    The Globe and Mail•10/9/26•Bullish

    4D molecular therapeutics CEO David Kirn sells $753k in company stock

    David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ:FDMT), sold company stock worth over $753,000 on October 5, 2026, through a pre-arranged trading plan. Despite a recent dip...

    Investing.com Nigeria•10/8/26•Neutral

    Chardan Capital Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $25

    Chardan Capital has initiated coverage on 4D Molecular Therapeutics (FDMT.US) with a Buy rating. The firm has set a target price of $25 for the company's stock.

    Moomoo•10/8/26•Bullish

    4D molecular therapeutics CEO David Kirn sells $753k in company stock

    David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ:FDMT), sold company stock worth $753,937 on October 5, 2026, through a pre-arranged 10b5-1 trading plan. Despite the stock being down about 9% in the past week...

    Investing.com•10/8/26•Neutral

    Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com

    This article announces the filing of Form 4 by 4D Molecular Therapeutics Inc for October 7. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change...

    Investing.com Nigeria•10/8/26•Somewhat-Bullish

    FDMT Valuation and Fair Value

    P/E
    -4.9x
    P/B
    2.2x
    See GNG's fair value

    FDMT Profitability: Margins, ROIC and FCF

    Operating margin
    -2037.0%
    Net margin
    -194.7%
    ROIC
    -36.5%
    ROE
    -43.2%
    FCF margin
    -169.7%

    FDMT Competitors

    CompanyTicker
    Inventiva SaIVA
    Pharming Group NVPHAR
    Design Therapeutics IncDSGN
    OmniAb Inc.OABI
    MiMedx Group IncMDXG
    Phreesia IncPHR
    Gyre Therapeutics Inc.GYRE
    Avalo Therapeutics IncAVTX

    Sector: Healthcare

    FDMT Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    2
    Buy
    9
    Hold
    1
    Sell
    0
    Strong Sell
    0

    FDMT Bull Case vs Bear Case

    Bull case

    • FDMT grew quarterly revenue 25107.0% year over year.
    • 91.7% of FDMT's analyst ratings are Buy or Strong Buy.

    Bear case

    • FDMT has a -194.7% net profit margin.
    • FDMT beat EPS estimates in 12.5% of its last 8 reported quarters.

    FDMT Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    14.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.05
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About FDMT

    Does FDMT pay dividends?

    4D Molecular Therapeutics Inc (FDMT) does not currently pay a regular dividend.

    What is FDMT's market cap?

    4D Molecular Therapeutics Inc (FDMT) has a market capitalization of $673.98M with a current stock price of $12.87.

    Related stocks

    Sector: Healthcare

    All stocks starting with F

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In